Journal
FUTURE ONCOLOGY
Volume 16, Issue 19, Pages 1359-1370Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2020-0050
Keywords
cancer; cardiac toxicity; panitumumab; risk factors
Categories
Funding
- National Natural Science Foundation of China [81673102, 81602791, 81803164]
- National Key Research and Development Program of China [2016YFC0105409]
- Youth Foundation of Shanghai Health and Family Planning Commission [20164Y0066]
- Clinical Research Plan of SHDC [16CR1037B]
- Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20171904]
- Shanghai Jiaotong University Translational Medicine Fund Support [ZH2018QNA54]
- Special construction of integrated Chinese and Western medicine in general hospital [ZHYY-ZXYJHZ X-2-201704, ZHYY-ZXYJHZ X-2201913]
Ask authors/readers for more resources
Aim: To evaluate the incidence and risk of cardiac toxicities associated with panitumumab in advanced cancer of Caucasian patients. Materials & methods: The incidence of cardiac toxicity was assessed by simple incidence rates and rates per 100 person-years. Univariate and multivariate Cox regression was conducted. Results: Panitumumab-containing therapy significantly increased the risk of developing cardiac arrhythmias (p = 0.036), but not for any cardiac event (p = 0.24) or ischemic event (p = 0.087). The absolute rate of developing cardiac arrhythmia was 10.0 events versus 7.5 events per 100 person-years. Pre-existing hypertension (p = 0.033), history of cardiac disease (p = 0.055) or panitumumab usage (p = 0.046) were risk factors for cardiac arrhythmias. Conclusion: The addition of panitumumab to chemotherapy increases the risk of developing cardiac arrhythmia, but not for any cardiac toxicity or ischemic events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available